Moderna's Covid-19 vaccine shows similar immune response in old and young
Aug 28 2020
The drug developer is one of the leading United States contenders in the race to develop a safe and effective jab against COVID-19 and its candidate, mRNA-1273, is already in the Phase III stage of human testing.
The first patient to receive a dose was 37-year-old Cincinnati resident Jarelle Marshall.
China has been giving experimental coronavirus vaccines to groups facing high infection risks since July, a health official told state media.
The vaccine should begin producing a viral antigen which will activate a response in the body's immune system.
Moderna is now reporting interim data from the Phase 1 study, which includes new analysis from 20 additional people and details on how the vaccine performs in older people.
Researchers tested the virus in two groups of 10, the first between ages 56 and 70 and a second in elderly adults aged 71 and older. The doses were administered 28 days apart for each patient.
In addition to high levels of antibodies, the vaccine did not appear to result in any severe side effects, according to the Massachusetts-based company said.
The most common adverse reactions were fatigue, chills, headache and myalgia.
Dr. Jacqueline Miller, Moderna's head of infectious disease development, told a U.S. Centers for Disease Control and Prevention (CDC) panel the company plans to post weekly updates on enrollment of Black and Latino trial subjects on its website.
Even though it doesn't have any drugs on the market, the USA government gave Moderna almost $1 billion towards a vaccine development.
Moderna Inc. said it plans to provide 80 million doses of its experimental coronavirus shot to the European Union following a string of supply deals between vaccine developers and governments.
Moderna, along with several other drug makers, is developing a vaccine to treat the virus, which has been confirmed in more than 23.9 million people globally, with deaths from COVID-19 topping 820,000 reported, according to Johns Hopkins University.
"Hopefully we will get Covid-19 vaccine from WHO (World Health Organization) by June 2021". Its candidate, mRNA-1273, is already in the Phase III stage of human testing.